Ruxolitinib
Ruxolitinib is a medication classified as a Janus kinase (JAK) inhibitor. It works by blocking certain enzymes in the body that are involved in the development and progression of myelofibrosis and polycythemia vera, two rare blood disorders. By inhibiting these enzymes, ruxolitinib helps to reduce symptoms and slow down the progression of these diseases.Ruxolitinib is indicated for the treatment of myelofibrosis, a condition characterized by the abnormal development of scar tissue in the bone marrow, and polycythemia vera, a disorder characterized by the overproduction of red blood cells.
The dosage of ruxolitinib varies depending on the specific condition being treated, the patient's weight, and other individual factors. It is typically taken orally, with or without food, as directed by a healthcare professional.
Ruxolitinib is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. It should not be used in patients with severe liver impairment or during pregnancy unless the potential benefits outweigh the risks.
Patients taking ruxolitinib should undergo regular monitoring of blood cell counts and liver function tests. It should be used with caution in patients with a history of tuberculosis, hepatitis B or C, or other infections, as ruxolitinib may increase the risk of infection or reactivation of latent infections.
Common side effects of ruxolitinib may include anemia, thrombocytopenia, nausea, diarrhea, fatigue, and headache. Serious side effects such as severe infections, liver toxicity, and gastrointestinal perforation may occur less frequently. Patients experiencing any adverse effects should seek medical attention promptly.
Ruxolitinib may interact with certain medications, including strong CYP3A4 inhibitors and inducers, as well as drugs that affect the immune system. It is important to inform the healthcare provider about all medications, supplements, and herbal products being taken to avoid potential interactions.
